Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Molecular Partners (0QXX)

Molecular Partners Ag
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QXX
DateTimeSourceHeadlineSymbolCompany
06/03/202521:00UK RegulatoryMolecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024LSE:0QXXMolecular Partners Ag
28/02/202506:00UK RegulatoryMolecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference CallLSE:0QXXMolecular Partners Ag
12/01/202518:00UK RegulatoryMolecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancerLSE:0QXXMolecular Partners Ag
12/01/202518:00UK RegulatoryMolecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare ConferenceLSE:0QXXMolecular Partners Ag
17/12/202421:00UK RegulatoryMolecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in JanuaryLSE:0QXXMolecular Partners Ag
08/12/202417:00UK RegulatoryMolecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024LSE:0QXXMolecular Partners Ag
07/11/202421:00UK RegulatoryMolecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024LSE:0QXXMolecular Partners Ag
05/11/202421:00UK RegulatoryMolecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and ExpositionLSE:0QXXMolecular Partners Ag
31/10/202420:00UK RegulatoryMolecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-goingLSE:0QXXMolecular Partners Ag
25/10/202405:00UK RegulatoryMolecular Partners Announces Pricing of $20 Million Underwritten OfferingLSE:0QXXMolecular Partners Ag
22/10/202405:00UK RegulatoryMolecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin TherapeuticsLSE:0QXXMolecular Partners Ag
22/10/202405:00UK RegulatoryMolecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024LSE:0QXXMolecular Partners Ag
04/10/202405:00UK RegulatoryMolecular Partners Announces upcoming poster presentations at the 2024 SITC Annual MeetingLSE:0QXXMolecular Partners Ag
27/09/202405:00UK RegulatoryMolecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024LSE:0QXXMolecular Partners Ag
26/08/202420:00UK RegulatoryMolecular Partners Reports H1 2024 Corporate Highlights and FinancialsLSE:0QXXMolecular Partners Ag
14/06/202405:00UK RegulatoryMolecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024LSE:0QXXMolecular Partners Ag
11/06/202405:00UK RegulatoryMolecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024LSE:0QXXMolecular Partners Ag
19/04/202415:12UK RegulatoryLife Science Cares Launches in SwitzerlandLSE:0QXXMolecular Partners Ag
 Showing the most relevant articles for your search:LSE:0QXX